Novartis to seek full FDA approval for IgAN drug Vanrafia despite missing ph. 3 kidney function goal
It’s déjà vu all over again. Just as the kidney disease space becomes increasingly competitive, Novartis has found itself intending to turn a statistical miss into a regulatory win. | It’s déjà vu all ...
The table below is a review of notable updates that occurred in January 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results